Abionyx Pharma SA (ABNXp)

Overview

ABIONYX Pharma SA is a prominent biotech company engaged in the discovery and development of innovative therapies aimed at treating renal and ophthalmological diseases. Founded in 2005 and headquartered in Balma, France, the company was initially known as Cerenis Therapeutics Holding SA before rebranding to ABIONYX Pharma SA in August 2019. The company leverages advanced biotechnological approaches to meet critical healthcare needs in areas with significant unmet medical demands.

Products and Services

• CER-001: This advanced therapy is a composition of negatively-charged lipoprotein particles containing human recombinant apoA-I, the protein found in natural high-density lipoprotein (HDL), along with sphingomyelin and dipalmitoylphosphatidylglycerol, natural phospholipids. Designed to mimic the structural and functional biological properties of pre-beta HDL, CER-001 is intended for the treatment of patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia.

• CER-002: As a specific agonist for the peroxisome proliferator-activated receptor delta, CER-002 targets cardiovascular and metabolic diseases. This compound leverages the therapeutic potential of PPARδ agonism to offer a novel approach in the management of complex conditions, illustrating the company's dedication to addressing broad-spectrum metabolic and cardiovascular health issues.

• CER-209: This candidate drug focuses on the treatment of metabolic diseases affecting the liver, alongside conditions such as atherosclerosis and non-alcoholic steatohepatitis. CER-209 underscores ABIONYX Pharma SA’s commitment to pioneering treatments for metabolic and liver-related diseases, aiming to improve the quality of life for patients suffering from these conditions.